UCP1 and metabolic dysfunction-associated steatohepatitis: found that poly I:C, a TLR3 agonist, effectively reverse cell death and restore UCP1 expression in UCP1−/− NK cells, thereby inhibiting the progression of NASH to fibrosis (117).